GraniteShares Advisors LLC Sells 176 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

GraniteShares Advisors LLC reduced its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 13.4% during the fourth quarter, Holdings Channel reports. The fund owned 1,137 shares of the biopharmaceutical company’s stock after selling 176 shares during the period. GraniteShares Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $999,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Annis Gardner Whiting Capital Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals in the third quarter worth $26,000. Sunbelt Securities Inc. purchased a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at $25,000. Fortitude Family Office LLC purchased a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at $31,000. Bruce G. Allen Investments LLC purchased a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at $40,000. Finally, Sutton Wealth Advisors Inc. boosted its position in Regeneron Pharmaceuticals by 38.2% during the 3rd quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 13 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently commented on REGN shares. Sanford C. Bernstein started coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 target price for the company. Bank of America raised their target price on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a research report on Friday. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $1,189.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 9th. Truist Financial reaffirmed a “buy” rating and issued a $1,135.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, April 3rd. Finally, StockNews.com raised shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday. One analyst has rated the stock with a sell rating, four have issued a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $970.57.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, EVP Andrew J. Murphy sold 5,783 shares of the business’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the transaction, the executive vice president now owns 48,306 shares in the company, valued at $46,203,239.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Regeneron Pharmaceuticals news, EVP Andrew J. Murphy sold 5,783 shares of the business’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the transaction, the executive vice president now owns 48,306 shares in the company, valued at $46,203,239.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bonnie L. Bassler sold 827 shares of the business’s stock in a transaction on Tuesday, January 30th. The shares were sold at an average price of $959.00, for a total transaction of $793,093.00. Following the transaction, the director now owns 1,382 shares in the company, valued at approximately $1,325,338. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 13,729 shares of company stock worth $13,124,641. Insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN traded down $4.42 during trading hours on Tuesday, hitting $894.14. 615,755 shares of the stock traded hands, compared to its average volume of 495,922. The company has a quick ratio of 4.94, a current ratio of 5.69 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a 1 year low of $684.80 and a 1 year high of $998.33. The company has a market cap of $98.14 billion, a price-to-earnings ratio of 25.86, a price-to-earnings-growth ratio of 2.64 and a beta of 0.11. The stock has a 50 day moving average price of $956.81 and a 200 day moving average price of $889.95.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, topping the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The company had revenue of $3.43 billion for the quarter, compared to analysts’ expectations of $3.29 billion. During the same quarter in the previous year, the business posted $10.96 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up .6% on a year-over-year basis. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 38.18 EPS for the current fiscal year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.